In a filing, Kiniksa Pharmaceuticals International Plc revealed its CHIEF OPERATING OFFICER Tessari Eben unloaded Company’s shares for reported $0.26 million on Jan 13 ’25. In the deal valued at $18.24 per share,14,000 shares were sold. As a result of this transaction, Tessari Eben now holds 88,975 shares worth roughly $1.67 million.
Then, Tessari Eben bought 14,000 shares, generating $255,390 in total proceeds.
Before that, Tessari Eben sold 23,017 shares. Kiniksa Pharmaceuticals International Plc shares valued at $470,467 were divested by the CHIEF OPERATING OFFICER at a price of $20.44 per share. As a result of the transaction, Tessari Eben now holds 95,975 shares, worth roughly $1.8 million.
Jefferies initiated its Kiniksa Pharmaceuticals International Plc [KNSA] rating to a Buy in a research note published on September 13, 2024; the price target was $40. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early May with a ‘”an Overweight”‘ rating. BofA Securities also remained covering KNSA and reiterated its “Buy” recommendation on June 29, 2020. BofA/Merrill started covering the stock on April 01, 2020. It rated KNSA as “a Buy”.
Price Performance Review of KNSA
On Tuesday, Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] saw its stock fall -0.74% to $18.74. Over the last five days, the stock has lost -7.14%. Kiniksa Pharmaceuticals International Plc shares have fallen nearly -5.26% since the year began. Nevertheless, the stocks have risen 2.91% over the past one year. While a 52-week high of $28.15 was reached on 01/28/25, a 52-week low of $16.56 was recorded on 01/13/25. SMA at 50 days reached $20.27, while 200 days put it at $21.98.
Levels Of Support And Resistance For KNSA Stock
The 24-hour chart illustrates a support level at 18.58, which if violated will result in even more drops to 18.43. On the upside, there is a resistance level at 19.04. A further resistance level may holdings at 19.35. The Relative Strength Index (RSI) on the 14-day chart is 40.76, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.37, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.13%. Stochastics %K at 33.43% indicates the stock is a holding.
How much short interest is there in Kiniksa Pharmaceuticals International Plc?
A steep rise in short interest was recorded in Kiniksa Pharmaceuticals International Plc stocks on 2025-01-15, dropping by -1.15 million shares to a total of 2.11 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 3.26 million shares. There was a decline of -54.44%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 11, 2019 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $26 price target.
